# A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation

> **NCT01304810** · — · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 300 (actual)

## Conditions studied

- Smoking Cessation
- Nicotine Dependence

## Interventions

- **BIOLOGICAL:** NicVAX vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01304810
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2012-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01304810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01304810, "A Follow-up Study to Assess Long-term Immunogenicity and Safety of NicVAX/Placebo as an Aid to Smoking Cessation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01304810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*